United States - English - NLM (National Library of Medicine)

smith & nephew, inc - collagenase clostridium histolyticum (unii: 9x7o8v25it) (collagenase clostridium histolyticum - unii:9x7o8v25it) - collagenase clostridium histolyticum 250 [arb'u] in 1 g - collagenase santyl◊  ointment is indicated for debriding chronic dermal ulcers 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 and severely burned areas. 3, 4, 5, 7, 16, 19, 20, 21 collagenase santyl◊  ointment is contraindicated in patients who have shown local or systemic hypersensitivity to collagenase.

United States - English - NLM (National Library of Medicine)

endo pharmaceuticals inc. - collagenase clostridium histolyticum (unii: 9x7o8v25it) (collagenase clostridium histolyticum - unii:9x7o8v25it) - collagenase clostridium histolyticum 0.9 mg - xiaflex is indicated for the treatment of adult patients with dupuytren’s contracture with a palpable cord. xiaflex is indicated for the treatment of adult men with peyronie’s disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. xiaflex is contraindicated in: - the treatment of peyronie’s plaques that involve the penile urethra due to potential risk to this structure. - patients with a history of hypersensitivity to xiaflex or to collagenase used in any other therapeutic application or application method [see warnings and precautions (5.4)] . pregnancy category b there are no adequate and well-controlled studies of xiaflex in pregnant women. because animal reproduction studies are not always predictive of human response, xiaflex should be used during pregnancy only if clearly needed. risk summary based on animal data, xiaflex is not predicted to increase the risk for major developmental abnormalities in humans. human data human pharmacokinetic studies

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - collagenase clostridium histolyticum -

Israel - English - Ministry of Health

megapharm ltd - collagenase clostridium histolyticum - powder and solvent for solution for injection - collagenase clostridium histolyticum 0.9 mg/vial - collagenase clostridium histolyticum - xiapex is indicated for the treatment of dupuytren’s contracture in adult patients with a palpable cord.the treatment of adult men with peyronie’s disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.

United States - English - NLM (National Library of Medicine)

viatrexx bio incorporated - collagen 8x, 200k - to help support collagen formation

Australia - English - Department of Health (Therapeutic Goods Administration)

bard australia pty ltd - 47201 - collagen haemostatic agent - avitene? (mch) is an absorbable topical hemostatic agent prepared as a dry, sterile, fibrous, water insoluble partial hydrochloric acid salt of purified bovine corium collagen. avitene? (mch) is used in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical.

United States - English - NLM (National Library of Medicine)

endo aesthetics llc - collagenase clostridium histolyticum (unii: 9x7o8v25it) (collagenase clostridium histolyticum - unii:9x7o8v25it) - qwo is indicated for the treatment of moderate to severe cellulite in the buttocks of adult women. qwo is contraindicated in: - patients with a history of hypersensitivity to collagenase or to any of the excipients [see warnings and precautions (5.1)] . - the presence of infection at the injection sites. risk summary there are no available data on collagenase clostridium histolyticum use in pregnant women to evaluate for a drug- associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. following subcutaneous injection, the systemic concentrations for qwo were below the bioanalytical assay limit of quantification [see clinical pharmacology (12.3)] . in animal reproduction studies, intravenous administration of collagenase clostridium histolyticum to pregnant rats during organogenesis at doses up to 0.13 mg/rat (43 × human equivalent dose [hed] on a mg/kg basis) revealed no evidence of harm to the fetus. the estimated background risk of major birth defects and miscarriage for

Australia - English - Department of Health (Therapeutic Goods Administration)

osstem australia pty ltd - 58709 - collagen dental regeneration membrane - ossmem is absorbable barrier membrane using high purity type i collagen. there is no difference to use both front and backside, and it is possible to apply for guided bone regeneration (gbr) and guided tissue regeneration (gtr). hard-type membrane (ocmh) has a dense structure with low porosity while soft-type membrane (ocms) has a sponge-type structure with high porosity. therefore, the hard-type membrane has higher tensile strength and harder physical property than the soft-type membrane. ossmem is an absorbent material that acts as a barrier between the gingiva and the alveolar bone and induces the regeneration of periodontal tissue. it does not require any secondary treatment for separate removal.

Australia - English - Department of Health (Therapeutic Goods Administration)

nature's family australia pty ltd - sodium ascorbate, quantity: 50 mg; collagen, quantity: 350 mg - capsule - excipient ingredients: soy polysaccharide; magnesium stearate; colloidal anhydrous silica; hypromellose; purified water - nature?s family vita collagen acts as an efficient form of supplement assisting in the building and maintenance of the human body?s structural supports relying on natural protein to function. these may include ligaments, joints, skin, hair and nails - and collagen enables these parts of the body to retain their strength in resiliency and maintain revitalised appearance. with nature?s family vita collagen, skin conditions may be improved in appearance and on a cellular level, boost the body?s immune system and assist in the improvement of general well-being. benefits: helps improve skin conditions helps revitalise skill cells helps boost immune system supports general well being

Australia - English - Department of Health (Therapeutic Goods Administration)

geistlich pharma australia pty ltd - 47968 - dental bone matrix implant, animal-derived - a combined kit containing geistlich bio-oss collagen 100mg and geistlich bio-gide 16 x 22 mm. bio-oss: the spongy consistency of the material allows simple trimming. the collagen facilitates adaptation to the defect site. the collagen is slowly resorbed over several weeks. bio-gide: the duration of barrier function ensures sufficient bone formation time for the indications. the fibrous microstructure is hydrophilic and retains its structural integrity when wet. to be used in the regeneration of bone defects. geistlich bio-oss collagen is intended to be used in the treatment of hard tissue defects in oral-maxillofacial surgery; and is indicated in the following clinical situations: bone deficiencies in the alveolar ridge; dentofacial anomalies and malformations; and geistlich bio-gide is intended to be used in the treatment of hard and soft tissue defects in oral and maxillofacial surgery. the concerned hard and soft tissue defects may be surgically created or result from traumatic injuries, pathological conditions, medical treatments and therapies, or history of personal lifestyle habits; and is indicated to be used in the surgical treatment of the following clinical conditions: tissue deficiencies in the alveolar ridge; dentofacial anomalies and malformations.